Cost analysis of catheter ablation for paroxysmal atrial fibrillation

Rukshen Weerasooriya, Pierre Jaïs, Jean Yves Le Heuzey, Christophe Scaveé, Kee Joon Choi, Laurent Macle, Florence Raybaud, Mélèze Hocini, Dipen C. Shah, Thomas Lavergne, Jacques Clémenty, Michel Haïssaguerre

Research output: Contribution to conferenceConference presentation/ephemerapeer-review

51 Citations (Scopus)

Abstract

RF ablation for paroxysmal atrial fibrillation (PAF) is a curative treatment, which when successful, eliminates the need to take antiarrhythmic drugs, be anticoagulated, and have recurrent physician visits or hospital admissions. The authors performed a retrospective cost comparison of RF ablation versus drug therapy for PAF. The study population consisted of 118 consecutive patients with symptomatic, drug refractory PAF who underwent 1.52 ± 0.71 RF ablation procedures (range 1-4) for PAF. During a follow-up of 32 ± 15 weeks, 85 (72%) patients remained free of clinical recurrence in absence of antiarrhythmic drugs. The cost of RF ablation was calculated in the year 2001 euros on the basis of resource use. The mean cost of pharmacologic treatment prior to ablation was 1,590 euros/patient per year. The initial cost of RF ablation for PAF was 4,715 euros, then 445 euros/year. After 5 years, the cost of RF ablation was below that of ongoing medical management, and continued to diverge thereafter. RF catheter ablation may be a cost-effective alternative to long-term drug therapy in patients with symptomatic, drug refractory PAF.
Original languageEnglish
Number of pages3
DOIs
Publication statusPublished - 1 Jan 2003

Fingerprint

Dive into the research topics of 'Cost analysis of catheter ablation for paroxysmal atrial fibrillation'. Together they form a unique fingerprint.

Cite this